2-bromo-N-(5-(4-p-tolylthiazol-2-ylcarbamoyl)thiazol-2-yl)thiazole-5-carboxamide → 2-(propylamino)-N-(5-(4-p-tolylthiazol-2-ylcarbamoyl)thiazol-2-yl)thiazole-5-carboxamide
반응식
Br[C:2]1[S:3][C:4]([C:7]([NH:9][C:10]2[S:11][C:12]([C:15](=[O:29])[NH:16][C:17]3[S:18][CH:19]=[C:20]([C:22]4[CH:27]=[CH:26][C:25]([CH3:28])=[CH:24][CH:23]=4)[N:21]=3)=[CH:13][N:14]=2)=[O:8])=[CH:5][N:6]=1>C(N)CC>[CH2:5]([NH:6][C:2]1[S:3][C:4]([C:7]([NH:9][C:10]2[S:11][C:12]([C:15](=[O:29])[NH:16][C:17]3[S:18][CH:19]=[C:20]([C:22]4[CH:27]=[CH:26][C:25]([CH3:28])=[CH:24][CH:23]=4)[N:21]=3)=[CH:13][N:14]=2)=[O:8])=[CH:5][N:6]=1)[CH2:4][CH3:7]참가 물질
3
실험 절차
A solution of 2-bromo-N-(5-(4-p-tolylthiazol-2-ylcarbamoyl)thiazol-2-yl)thiazole-5-carboxamide (15 mg, 0.03 mmol) in neat propylamine (0.5 mL) was stirred at reflux for 24 hrs. The solvent was evaporated and the crude product was purified by column chromatography (0%-5% MeOH/AcOEt) yielding 2-(propylamino)-N-(5-(4-p-tolylthiazol-2-ylcarbamoyl)-thiazol-2-yl)thiazole-5-carboxamide (15 mg, 17%).